Market Place
Sourcing Support
IN8bio to Present New Preclinical Data on T cell Engager at Meeting
31 Mar 2025 //
GLOBENEWSWIRE
IN8bio at 11th Annual Immuno-Oncology 360° Conference 2025
18 Mar 2025 //
GLOBENEWSWIRE
IN8bio Reports 2024 Financial Results and Business Highlights
13 Mar 2025 //
GLOBENEWSWIRE
IN8bio Unveils Gamma-Delta TCE Platform For Cancer, Autoimmune
03 Mar 2025 //
GLOBENEWSWIRE
IN8bio to Present at TD Cowen 45th Annual Health Care Conference
26 Feb 2025 //
GLOBENEWSWIRE
IN8bio to Present at H.C. Wainwright Cell Therapy Conference
24 Feb 2025 //
GLOBENEWSWIRE
IN8bio Highlights Durable Remissions In Ph1 High-Risk AML
14 Feb 2025 //
GLOBENEWSWIRE
IN8bio Reports Positive Results from Phase 1 Leukemia Trial
11 Feb 2025 //
GLOBENEWSWIRE
IN8bio to Present at Biotech Showcase 2025 in San Francisco
06 Jan 2025 //
GLOBENEWSWIRE
IN8bio Reports Progression-Free Survival For INB-100 In Leukemias
10 Dec 2024 //
GLOBENEWSWIRE
IN8bio Reports Durable in INB-200 Ph 1 Trial at SNO Annual Meeting
25 Nov 2024 //
GLOBENEWSWIRE
IN8bio to Present at 2024 SNO Annual Meeting
12 Nov 2024 //
GLOBENEWSWIRE
IN8bio Reports Q3 2024 Financial Results & Corporate Highlights
12 Nov 2024 //
GLOBENEWSWIRE
IN8bio Announces Presentation at ASH 2024 Annual Meeting
05 Nov 2024 //
GLOBENEWSWIRE
IN8bio Announces Pricing of $12.4 Million Private Placement
01 Oct 2024 //
GLOBENEWSWIRE
IN8bio Halts Ph 2 Glioblastoma Trial, Focuses on Leukemia Therapy After Layoffs
05 Sep 2024 //
FIERCE BIOTECH
IN8bio Prioritizes INB-100 For Acute Myeloid Leukemia
04 Sep 2024 //
GLOBENEWSWIRE
IN8bio to Present at H.C. Wainwright 26th Annual Global Investment Conference
29 Aug 2024 //
GLOBENEWSWIRE
IN8bio Reports 100% AML Remission, FDA Guidance For INB-100 Trial
12 Aug 2024 //
GLOBENEWSWIRE
IN8bio to Present at H.C. Wainwright Immune Cell Engager Virtual Conference
24 Jun 2024 //
GLOBENEWSWIRE
IN8bio Shows 100% 1-Year Complete Remission With INB-100 In Phase 1
13 Jun 2024 //
GLOBENEWSWIRE
IN8bio`s INB-200 Progression-Free Survival Update At ASCO 2024
03 Jun 2024 //
GLOBENEWSWIRE
IN8bio to Present at International Society for Cell & Gene Therapy (ISCT) 2024
24 May 2024 //
GLOBENEWSWIRE
In8bio Inb-200 Glioblastoma Data: Phase 1 Study At 2024 Asco
23 May 2024 //
GLOBENEWSWIRE
IN8bio Announces Upcoming Presentation At EHA 2024 Congress
14 May 2024 //
GLOBENEWSWIRE
IN8bio Shows Robust Gamma-Delta T Cell Therapy Manufacturing At ASGCT 2024
13 May 2024 //
GLOBENEWSWIRE
IN8bio Q1 2024 Financials And Corporate Highlights
09 May 2024 //
GLOBENEWSWIRE
IN8bio Doses First Patient in Ph2 INB-400 Newly Diagnosed GBM Trial
30 Apr 2024 //
GLOBENEWSWIRE
IN8bio Presents at ASGCT 2024 Annual Meeting
24 Apr 2024 //
GLOBENEWSWIRE
IN8bio to Present at Noble Capital Virtual Healthcare Conference
16 Apr 2024 //
GLOBENEWSWIRE
IN8bio Unveils Gamma-Delta nsCAR-T Data at AACR 2024
09 Apr 2024 //
GLOBENEWSWIRE
IN8bio Reports Fourth Quarter and Full-Year 2023 Financial Results
14 Mar 2024 //
GLOBENEWSWIRE
IN8bio to Present Preclinical Data on Novel Gamma-Delta CAR Platform Candidate
05 Mar 2024 //
GLOBENEWSWIRE
IN8bio to Present at Upcoming Investor Conferences
26 Feb 2024 //
BUSINESSWIRE
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy
14 Feb 2024 //
GLOBENEWSWIRE
IN8bio Highlights Company Accomplishments and Outlines 2024 Pipeline Goals
04 Jan 2024 //
GLOBENEWSWIRE
IN8bio Announces Pricing of Financing Totaling up to $46.9M in Private Placement
11 Dec 2023 //
GLOBENEWSWIRE
IN8bio Announces Positive Update of Patients in Ph 1 of INB-100 in Leukemia
11 Dec 2023 //
GLOBENEWSWIRE
IN8bio Appoints Dr. Corinne Epperly to Board of Directors
07 Dec 2023 //
GLOBENEWSWIRE
IN8bio to Host Investor Call at 8:30 AM ET on Tuesday, December 12
05 Dec 2023 //
GLOBENEWSWIRE
IN8bios INB-200 Demonstrates Extended Progression-Free Survival in Glioblastoma
20 Nov 2023 //
GLOBENEWSWIRE
IN8bio to Present Data Highlighting Potential of INB-200 and INB-400
10 Nov 2023 //
GLOBENEWSWIRE
IN8bio Reports Third Quarter 2023 Financial Results
09 Nov 2023 //
GLOBENEWSWIRE
Revive Therapeutics Enters into Agreement with Lawson Health Research Institute
06 Nov 2023 //
GLOBENEWSWIRE
IN8bio Presents Biologic Correlative Data from the INB-200 Phase 1 Trial
06 Nov 2023 //
GLOBENEWSWIRE
IN8bio Presents Positive Data from Induced Pluripotent Stem Cell (iPSC) Platform
03 Nov 2023 //
GLOBENEWSWIRE
IN8bio to Present New Positive Data from Phase 1 Trial of INB-100
02 Nov 2023 //
GLOBENEWSWIRE
IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100
12 Oct 2023 //
GLOBENEWSWIRE
IN8bio Announces Presentations at the SITC 38th Annual Meeting
29 Sep 2023 //
GLOBENEWSWIRE
IN8bio to Host Research & Development Day on its Gamma-Delta T cell Therapies
26 Sep 2023 //
GLOBENEWSWIRE
IN8bio to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference
20 Sep 2023 //
GLOBENEWSWIRE
IN8bio Strengthens Intellectual Property Portfolio with Granted Global Patents
19 Sep 2023 //
GLOBENEWSWIRE
IN8bio to Participate at H.C. Wainwright 25th Annual Global Conference
06 Sep 2023 //
GLOBENEWSWIRE
IN8bio to Present at the H.C. Wainwright Immune Cell Engager Virtual Conference
15 Aug 2023 //
GLOBENEWSWIRE
IN8bio Reports Second Quarter 2023 Financial Results
10 Aug 2023 //
GLOBENEWSWIRE
IN8bio Expands Capabilities with the Grand Opening of R&D Facility
08 Aug 2023 //
GLOBENEWSWIRE
IN8bio Announces Positive INB-200 Phase 1 Data Update in Glioblastoma
05 Jun 2023 //
GLOBENEWSWIRE
IN8bio`s DeltEx Gamma-Delta T Cells Show Promise in Targeting Ovarian Cancer
17 May 2023 //
GLOBENEWSWIRE
IN8bio Reports First Quarter 2023 Financial Results & Provides Corporate Update
12 May 2023 //
GLOBENEWSWIRE
IN8bio Announces New Preclinical Data in Ovarian Cancer at ASGCT
02 May 2023 //
GLOBENEWSWIRE
